collection
MENU ▼
Read by QxMD icon Read
search

Psychopharmacology Institute

shared collection
4 papers 0 to 25 followers
https://www.readbyqxmd.com/read/26757416/brexpiprazole-for-the-treatment-of-schizophrenia-a-review-of-this-novel-serotonin-dopamine-activity-modulator
#1
REVIEW
Joseph McEvoy, Leslie Citrome
Brexpiprazole is an antipsychotic medication and received approval by the U.S. Food and Drug Administration for the treatment of schizophrenia in July 2015. Brexpiprazole acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A and at adrenergic alpha1B and alpha2C receptors. Compared with aripiprazole, brexpiprazole is more potent at 5-HT1A receptors and displays less intrinsic activity at D2 receptors. The recommended dose range of brexpiprazole for the treatment of schizophrenia is 2-4 mg/day; the recommended titration schedule is to start with 1 mg/day and increase to 2 mg/day on Day 5 to Day 7, then to 4 mg/day on Day 8...
2016: Clinical Schizophrenia & related Psychoses
https://www.readbyqxmd.com/read/26324298/brexpiprazole-a-new-antipsychotic-following-in-the-footsteps-of-aripiprazole
#2
EDITORIAL
Donald C Goff
No abstract text is available yet for this article.
September 1, 2015: American Journal of Psychiatry
https://www.readbyqxmd.com/read/25373131/pros-and-cons-of-approved-therapies-for-bipolar-depression-and-ongoing-unmet-needs
#3
Susan L McElroy
Patients with bipolar disorder spend more time depressed than manic, but fewer clinical trials have been conducted investigating treatments for bipolar depression than for bipolar mania. Olanzapine-fluoxetine combination, quetiapine, and lurasidone are the only FDA-approved treatments for bipolar depression. Clinical trials of these drugs show similar efficacy but different side effect profiles. Clinicians, therefore, should consider possible adverse events and individual patient characteristics when selecting treatments...
October 2014: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/24677189/the-effects-of-novel-and-newly-approved-antipsychotics-on-serum-prolactin-levels-a-comprehensive-review
#4
REVIEW
J Peuskens, L Pani, J Detraux, M De Hert
Since the 1970s, clinicians have increasingly become more familiar with hyperprolactinemia (HPRL) as a common adverse effect of antipsychotic medication, which remains the cornerstone of pharmacological treatment for patients with schizophrenia. Although treatment with second-generation antipsychotics (SGAs) as a group is, compared with use of the first-generation antipsychotics, associated with lower prolactin (PRL) plasma levels, the detailed effects on plasma PRL levels for each of these compounds in reports often remain incomplete or inaccurate...
May 2014: CNS Drugs
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"